Anifrolumab in systemic lupus erythematosus

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune condition with diverse clinical presentations.
• Current first-line treatments include hydroxychloroquine and corticosteroids, with further immunomodulatory agents used for severe or organ-specific disease.
• Type 1 interferons play a significant role in SLE pathogenesis.

Approach:

• This review examines the pathophysiology of type 1 interferons in SLE.
• It evaluates the clinical trial data (MUSE, TULIP-1, TULIP-2) supporting the approval of anifrolumab.
• Anifrolumab is a novel biologic targeting the type 1 interferon pathway.

Key Points:

• Anifrolumab is the first approved type 1 interferon pathway inhibitor for SLE.
• Clinical trials demonstrated anifrolumab's efficacy in reducing overall disease activity.
• Significant improvements were observed in skin and musculoskeletal manifestations of SLE.
• The drug can help reduce the need for corticosteroid therapy.
• Anifrolumab demonstrated an acceptable safety profile in clinical studies.

Conclusions:

• Anifrolumab offers a new therapeutic option for patients with systemic lupus erythematosus.
• It effectively targets the type 1 interferon pathway implicated in SLE.
• The drug reduces disease activity, particularly skin and joint symptoms, and corticosteroid dependence.